Migraine

The safety and efficacy profiles of ubrogepant for acute migraines were not affected by concomitant preventive medication.
Read More

AbbVie announced that the FDA approved atogepant (QULIPTA) for the prevention of episodic migraines in adults.
Read More

A 3-month course of clopidogrel after transcatheter atrial septal defect closure was sufficient to prevent new-onset migraine attacks in most patients for 1 year.
Read More

Eptinezumab infusion within 1 to 6 hours of migraine onset was associated with significantly faster relief of headache pain and symptoms compared with placebo.
Read More

Prolonged infusion of vasoactive intestinal polypeptide was shown to induce migraine accompanied by dilation of the superficial temporal artery.
Read More

Rimegepant, a medication indicated for acute migraine relief, also may be efficacious as a preventive therapy by reducing the number of days per month that patients experience migraine.
Read More

A recent open-label study found that improvements in migraine frequency and severity with erenumab for episodic migraines were durable and not associated with any new safety concerns.
Read More

In a follow-up study to an intervention trial that was stopped for futility, children and adolescents with migraines showed long-lasting improvements in headache frequency regardless of their initial treatment.
Read More

Migraines may be classified into 3 subtypes based on headache intensity, frequency, and the presence of photophobia and phonophobia, according to a new analysis.
Read More

Results of a recent study have shown that simvastatin (Zocor) plus vitamin D is effective for the prevention of headache in adults with episodic migraine.
Read More

Page 1 of 2

Subscribe to Value-Based Care in Neurology

Stay up to date with the latest news in neurology by subscribing to receive the free VBCN e‑Newsletter.